公开(公告)号：US4517125A

公开(公告)日：1985-05-14

申请号：US463616

申请日：1983-02-03

申请人： Hiroaki Takayama ,  Sachiko Yamada ,  Keiko Nakayama ,  Tatsuo Suda

发明人： Hiroaki Takayama ,  Sachiko Yamada ,  Keiko Nakayama ,  Tatsuo Suda

IPC分类号： C07C401/00 ,  C07D319/02 ,  C07J9/00

CPC分类号： C07D319/02 ,  C07C401/00

摘要： There are disclosed 6,19-epidioxyvitamin D.sub.3 derivatives which are represented by the formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each a hydrogen atom or a hydroxyl group; when R.sub.1 is a hydrogen atom, R.sub.2 represents a hydroxyl group and R.sub.3 is a hydrogen atom or a hydroxyl group; when both R.sub.1 and R.sub.2 represent a hydroxyl group, R.sub.3 is a hydrogen atom or a hydroxyl group; and when R.sub.1 is a hydroxyl group and R.sub.2 is a hydrogen atom, R.sub.3 represents a hydroxyl group. The compounds are highly capable of inducing differentiation of human myeloid leukemia cells with minimum effects on calcium metabolism and are useful as an agent to treat leukemia.

摘要翻译： 公开了由式（1）表示的6,19-表维生素D3衍生物，其中R1，R2和R3各自为氢原子或羟基; 当R 1是氢原子时，R 2表示羟基，R 3是氢原子或羟基; 当R1和R2都表示羟基时，R3是氢原子或羟基; 当R 1为羟基且R 2为氢原子时，R 3表示羟基。 该化合物能够以最小的钙代谢作用诱导人类骨髓性白血病细胞的分化，并且可用作治疗白血病的药剂。